Display options
Cite
Lendrem D, Senn SJ, Lendrem BC, et al. R&D productivity rides again?. Pharm Stat. 2014;14(1):1-3doi: 10.1002/pst.1653.
Lendrem, D., Senn, S. J., Lendrem, B. C., & Isaacs, J. D. (2015). R&D productivity rides again?. Pharmaceutical statistics, 14(1), 1-3. https://doi.org/10.1002/pst.1653
Lendrem, Dennis, et al. "R&D productivity rides again?." Pharmaceutical statistics vol. 14,1 (2015): 1-3. doi: https://doi.org/10.1002/pst.1653
Lendrem D, Senn SJ, Lendrem BC, Isaacs JD. R&D productivity rides again?. Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Epub 2014 Oct 22. PMID: 25336017.
Copy Download .nbib Format: NLM
Share it on

Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Epub 2014 Oct 22.

R&D productivity rides again?.

Pharmaceutical statistics

Dennis Lendrem, Stephen J Senn, B Clare Lendrem, John D Isaacs

Affiliations

  1. Institute of Cellular Medicine, Newcastle University, UK.

PMID: 25336017 DOI: 10.1002/pst.1653

Abstract

A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned the corner' in 2008 and is 'on the comeback trail'. We believe that this analysis is flawed and most probably wrong. We present an alternative analysis of these same data to suggest that the industry is not yet 'out of the woods' and suggest that many of the systemic issues affecting pharmaceutical R&D productivity are still being resolved.

Copyright © 2014 John Wiley & Sons, Ltd.

Keywords: R&D costs; R&D productivity; costs; development; pharmaceutical industry; pharmaceutical innovation crisis; strategy

MeSH terms

Publication Types

Grant support